Vitiligo in Children: A Review of Conventional Treatments

Serena Gianfaldoni1,2, Uwe Wollina2, Georgi Tchernev3, Jacopo Lotti4, Katlein França5, Torello Lotti6

1University G. Marconi of Rome - Dermatology and Venereology, University G. Marconi of Rome, Rome, Italy; 2Städtisches Klinikum Dresden, Department of Dermatology and Venereology, Dresden, Sachsen, Germany; 3Medical Institute of Ministry of Interior Department of General, Vascular and Abdominal Surgery, Sofia, Bulgaria; 4University G. Marconi of Rome - Dept. of Nuclear, Subnuclear and Radiation Physics, Rome, Italy; 5University of Miami School of Medicine Ringgold standard institution, Miami, Florida, United States and Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Universita Degli Studi “G. Marconi”, Rome, Italy; 6University G. Marconi of Rome, Dermatology and Venereology, Rome, Italy

Abstract

Vitiligo is an important skin disease of childhood, which may lead to deep psychological trauma, resulting in a poor quality of life and low self-esteem. The Authors discuss a short review of the more conventional therapies available for the treatment of vitiligo in children.

Introduction

Vitiligo is an acquired, chronic, maybe autoimmune, pigmented disorder characterised by white macules and patches, due to the progressive loss of cutaneous melanocytes and to an abnormality in their normal function [1].

Usually, it starts in childhood or young adult: it has been estimated that about 50% of patients develop vitiligo before the age of 20 years and about 25% of them develop the disease before the age of 8, with a mean age of 4 - 5 years [2].

In pediatric age, vitiligo may represent a psychological trauma for both patients and their parents, resulting in emotional disorders (e.g. anxiety, depression), poor quality of life scores, and low self-esteem [3].

Topical treatments

Topical corticosteroids (TCs)

The efficacy of topical corticosteroids in the treatment of vitiligo, especially of localised forms on the face and other body’s area, is well - known since long time [4].
Table 1: Current traditional therapeutic options for vitiligo in children

| Treatment modality | Drugs | Mechanism of action | Side effect |
|--------------------|-------|---------------------|-------------|
| Topical treatments | Calcineurin inhibitors | Repigmentation, immunomodulation | Burning sensation, erythema, transient pruritus; risk of malignancies? |
| | Calcipotriol | | Transient burning or irritation |
| | Corticosteroids | Repigmentation, immunomodulation | Epidermal atrophy, striae, telangiectasia, glaucoma, tachyphylaxis, hypothalamic-pituitary axis suppression, Cushing’s syndrome, growth retardation |
| Systemic treatments | Corticosteroids | Immuno modulation | Glaucoma, tachyphylaxis, hypothalamic-pituitary axis suppression, Cushing’s syndrome, growth retardation |
| Phototherapies | PUVA (12yr), Topical PUVA, Topical PUVA sol, nbUVB | Repigmentation, immunomodulation | Erythema, itching or burning sensation; chronic actinic damage; psoralen toxicity (nausea, vomiting, abdominal pain, liver toxicity, cataracts) |

Other therapeutic options:
- Combined therapies (camouflage)
- Depigmentation therapy (monobenzyl ether of hydroquinone)
- Cognitive therapy and psychological support

Steroids act as anti-inflammatory and immunosuppressant agents. Even if different classes of steroids are now available, the mid- potent ones (e.g. betamethasone dipropionate 0.05% cream, 0.05% clobetasol propionate ointment) are usually preferred for the treatment of young patients. The drugs may be applied once or twice a day in consecutive or on alternate days. Different studies report a response rate of 45 - 60% in childhood vitiligo, with best outcome in inflammatory vitiligo [5].

Even if their use should be prolonged for several months, TCSs are quite safe only if used for few weeks, not more than 2 - 4 months, to avoid local side effects (e.g. atrophy, striae, telangiectasia, hypertrichosis, acneiform eruption) and systemic ones due to the percutaneous absorption (e.g. tachyphylaxis, suppression of hypothalamic-pituitary-adrenal axis, Cushing’s syndrome and growth retardation). In detail, the use of TCs on vitiligo patches of the face should be avoided or limited in time because of the higher risk of topical side effects, including glaucoma [6][7].

Topical calcineurin inhibitors (TCIs)

Topical calcineurin inhibitors (tacrolimus and pimecrolimus) are considered valid alternatives to TCSs for the treatment of localised forms of vitiligo. They act as immunomodulator agents: by blocking calcineurin, they inhibit the cytokines expression [8].

As TCSs, TCIs are indicated for the treatment of localised forms of vitiligo, also for the facial lesions where they seem to be safer than steroids. Usually, TCIs are prescribed twice a day.

Tacrolimus 0.1% seems to be more effective than pimecrolimus 1%, achieving a repigmentation rate similar to that of topical clobetasol propionate (0.05%) [9]. Pimecrolimus 1% is another valid option for the treatment of facial lesions, especially on the thinnest cutaneous areas, such as eyelids [10].

Usually, TCIs are safe and well tolerated. The most common side effects are burning sensation, transient pruritus and erythema at the side of the application. Because of the potential risk of malignancies (e.g. skin cancers and lymphoma), TCIs cannot be used in children < 2 years. The major limit to treat vitiligo with CIs is due to their costs [6].

Calcipotriol

Calcipotriol is a synthetic vitamin D3 analogue, which has been used for many years in the treatment of psoriasis for its ability to regulate the epidermal turnover.

Its use in vitiligo patients, start with the observations that its topical application, on psoriatic lesions, may cause perilesional hyperpigmentation. Even if the exact mechanism of action has to be elucidated, calcipotriol seems to stimulate melanogenesis and to halt the melanocytes destruction by T - cells [11].

Calcipotriol is applied once a day. It seems to be less effective than TCSs, with variable results in term of repigmentation rate. Interesting, calcipotriol seems to stimulate repigmentation in both treated and untreated skin, and to continue its action also after treatment termination, leading to hypothesise a systemic effect of the drug applied topically [12].

The drug is well tolerated, and the most common side effects are represented by a transient burning sensation or irritation at the site of application. The treated sites should not be exposed to phototherapy to avoid cutaneous hyperpigmentation.

Systemic treatment

Systemic corticosteroids (SCs)

In patients affected by unstable vitiligo, another therapeutic option is the systemic administration of corticosteroids (e.g. betamethasone, methylprednisolone), which seem to be useful to stop the progression of the disease and to induce repigmentation. Due to the potential well-described side effects, SCs are usually administered for a short period or in pulsed a regimen [13][14]. The dosages of SCs are usually decided by the patient’s characteristics. Recently, an oral mini-pulse therapy (OMP) has been proposed [15]. It consists of the morning intake of betamethasone (0.1 mg/kg body
weight) on two consecutive days in a week for 12 weeks. After that, patients have to assume 1 mg/month for the following three months. The clinical results seem to be good, with minimal risk of side effects.

**Phototherapies**

Ultraviolet radiations (UVR), both in the range of UVB and UVA, are considered as a first line therapy especially for extensive vitiligo, because of their good efficacy and tolerance. The effects of UVR are both immunosuppression and stimulation of the melanocytes activity [16].

Today, a range of phototherapies are now available: oral PUVA; topical cream PUVA, bath PUVA; PUVA sol; narrow-band UVB. Broad band UVB should no longer be used because of the sunburn risk and low efficacy.

**PUVA therapy**

PUVA therapy consists of the oral intake of a photosensitizing psoralen (e.g. 8 - methoxypsoralen, 5 - methoxysporalen or 4, 5, 8 - trimethylpsoralen) followed by exposure to photoactivating UVA light (320 - 400 nm). Treatment is performed 2 - 3 times a week, increasing the dose of UVA on the base of patient's response. Because of psoralen's toxicity (e.g. gastric and ocular damage), PUVA therapy should not be performed in children < 12. The rate of repigmentation after oral PUVA is about 75% in 50-60% of the children with vitiligo [4]. The possible side effects are due to both radiations and psoralens. While the most common short-time side effects are erythema, pruritus, xerosis and phototoxic reactions; the long-term ones include chronic actinic damage and carcinogenesis [16].

**Topical PUVA sol**

Similar treatment is the topical PUVA sol: after the topical application of a psoralen cream, the patient will be exposed to sunlight. Although the proven efficacy of the treatment, the risk of acute and chronic actinic damage are well documented [17].

**Bath PUVA**

Patients take a warm bath with 0.5 -1.0 mg/l 8 - MOP for 20 min before they are exposed to UVA [18][19].

**Narrow - band UVB (nb - UVB)**

Today, narrow-band UVB (nb - UVB, 311 nm) is considered a valid and safety therapy for vitiligo, especially for children due to the lack of psoralens. It consists in the exposure to nb - UVB at the starting dose of 0.1 mJ/cm², followed by 20% increasing dose of UVR on a weekly basis, accordingly to the clinical response. Treatment is well - tolerated. The commonest acute side effects are pruritus and erythema. Apart from supposed photo-damages, long-term side effects are yet to be determined [16]. Recent studies show how nb - UVB is more active than topical and oral PUVA, and that the repigmentation achieved with nb - UVB is more persistent and more similar to the colour of the unaffected skin [20].

**Combined treatments**

In the last years, different types of combined therapies have been proposed for the treatment of vitiligo in children.

Topical corticosteroids may be used in combination with calcipotriol [20]. This type of association seems to provide better clinical results in term of repigmentation and fast response, also in patients who did not have a response to the use of steroids alone. Moreover, the combination calcipotriol - corticosteroids reduce the side effects due to each drug, leading to a safer treatment.

In progressive vitiligo, TCs may be associated to the oral ones [21]. Apart from the risks due to the steroids therapy, the protocol seems to be effective in halting the progression of the disease and in inducing skin repigmentation. Finally, a study underlines also how the combination of OMP to nb - UVB phototherapy should be superior in the treatment of unstable vitiligo, then the systemic corticosteroids used alone [22].

Topical treatments may also be associated to phototherapies. For example, many studies show how nb-UVB combined with different topical drugs (e.g. Corticosteroids, vitamin D analogues, tacrolimus, pimecrolimus, pseudocatalase) could be more efficacy
than phototherapy alone \[16\][17][18][19][20][21][22][23][24]. In case of a combination, both TCIs and vitamin D analogues should be used after UVB, never before to avoid risks such as hyperpigmentation or skin cancer.

**Cosmetic camouflage**

Due to the deep psychological impact of vitiligo, which risks representing a real stigma for patients, the camouflage of vitiliginous areas is often recommended \[25\]. Today many products are available. The ideal cosmetic is non-allergenic, color matching, easy to apply and to remove, water resistant and cost-limited.

**Depigmentation therapy**

Unresponsive, widespread vitiligo or universal forms may be addressed to a total depigmentation therapy with 20% monobenzyl ether of hydroquinone (MBEH) \[26\].

**Cognitive therapy and psychological support**

Among the different type of vitiligo’s treatment, cognitive therapy and psychological support are strictly recommended for children with vitiligo and their parents, especially in the cases where it is clear the impact of the skin disease on their quality of life \[27\].

**Surgical therapies**

Surgical therapies are not recommended in childhood vitiligo and must to be limited to patients with stable localised lesions, unresponsive to the more conventional therapies. Surgical techniques in young children have to be also avoided because of their natural body growth in which lesions tend to extends, and they’re difficult to stand still in the post-operative time \[4\][5][6].

Today, different types of surgical techniques are available (Table 2). Among them, the suction blister epidermal grafting (SBEG) is the best choice for childhood vitiligo.

**Table 2: Surgical therapies for childhood vitiligo**

| Technique                        | Mechanism of actions                                                                 | Side effect                                                                                   |
|----------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| Surgical therapies               |                                                                                       |                                                                                             |
| Mini punch grafts, suction blister epidermal grafts (SBEG), thin Thiersch grafts, transplantation of epidermal cell suspension, cultured melanocyte suspension, and cultured epidermis, combined therapies | Correction of the pigmentary disease Cost factor and time consumption; inability to treat large areas; risk of infections; transient hyperpigmentation of recipient or donor site; risk of Koebner phenomenon at the graft site | Cost effective, quick, with low risk of infection |

Among the various surgical techniques, suction blister epidermal grafting (SBEG) has been found to be most convenient and effective for children and adolescents, with an excellent rate of repigmentation (>75%) in over 80% of patients \[28\]. Face and lips obtain best results \[29\].

Other surgical procedures include mini punch grafts; thin Thiersch grafts; transplantation of epidermal cell suspension, cultured melanocyte suspension, and cultured epidermis. Finally, there is the possibility to combine surgical techniques with medical treatments. An excellent example is the microdermabrasion of cutaneous lesions, followed by the topical use of pimecrolimus 1% cream \[30\].

Apart for the normal problems due to an intervention (e.g. risk of infection), the major problems due to surgical vitiligo therapies are represented by the necessity of expert equipment, the cost and the time consumption. Treatments are not indicated in the case of large vitiliginous areas and/or in case of active vitiligo. Finally, there are the risks of transient hyperpigmentation of recipient or donor site, and of Koebner phenomenon at the graft site.

**Conclusions**

Vitiligo’s treatment has two main goals: the first one is to halt the disease progression; the second one is to induce the lesions’ repigmentation, achieving an acceptable cosmetic result. In the last years, several therapeutic options, both medical and surgical, have been proposed for vitiligo. The choice of the best therapy for childhood vitiligo is based on various factors, such as patient’s age, psychological condition and expectation, distribution and extension of skin lesions, type of vitiligo (stable or not), availability and cost of the therapeutic options.

**References**

1. Abdel-Naser MB, Krüger-Krasagakes S, Krasagakis K et Al. Further evidence for the involvement of both cell-mediated and humoral immunity in generalized vitiligo. Pigment Cell Res. 1994; 7(1):1–8. https://doi.org/10.1111/j.1600-0749.1994.tb00013.x PMid:8072943

2. Halder RM, Grimes PE, Cowan CA, et Al. Childhood vitiligo. J Am Acad Dermatol. 1987; 16:948–54. https://doi.org/10.1016/S0190-9622(87)70119-4

3. Manzoni AP, Weber MB, Nagatomi AR et Al. Assessing depression and anxiety in the caregivers of pediatric patients with chronic skin disorders. An Bras Dermatol. 2013; 88(6):894-9. https://doi.org/10.1590/abd1906-4841.20131915 PMid:24474096 PMCid:PMC3900338

4. Tamesis ME, Morelli JG. Vitiligo treatment in childhood: A state of the art review. Paediatr Dermatol. 2010; 27:437–45. https://doi.org/10.1111/j.1525-1470.2010.01159.x PMid:20553403
5. Cho S, Kang HC, Hahn JH. Characteristics of vitiligo in Korean children. Pediatr Dermatol. 2000;17:189-93. https://doi.org/10.1046/j.1525-1470.2000.00174.x PMid:10886749

6. Amrinder Jit Kanwar, M Sendhil Kumaran. Childhood Vitiligo: Treatment Paradigms. Indian J Dermatol. 2012; 57(6): 466–474. https://doi.org/10.4103/0019-5154.103067 PMid:23248365 PMcid:PMC3519254

7. Gianfaldoni S, Hercogova J, Lotti T. The last frontier of Vitiligo repigmentation. The Asthetic J. 2014; 2014:34-37.

8. Pascual JC, Fleisher AB. Tacrolimus ointment (Protopic) for atopic dermatitis. Skin Therapy Lett. 2004; 9:1–5. PMid:15550992

9. Lepe V, Moncada B, Castanedo-Cazares JP, et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol. 2003; 139:581 – 585. https://doi.org/10.1001/archderm.139.5.581 PMid:12756094

10. Köse O, Arca E, Kurumlu Z. Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo. J Dermatolog Treat. 2010; 21:133-9. https://doi.org/10.3109/09546630903266761 PMid:20394489

11. Sarma N, Singh AK. Topical calcipotriol in childhood vitiligo: An Indian experience. Int J Dermatol. 2004; 43:856–9. https://doi.org/10.1111/j.1365-4658.2004.02344.x PMid:15533076

12. Sarma N. Topical calcipotriol in childhood vitiligo: an Indian experience. Int J Dermatol. 2004; 43:856-9. https://doi.org/10.1111/j.1365-4658.2004.02344.x PMid:15533076

13. Banerjee K, Barbhuiya JN, Ghosh AP et al. The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patient. Indian J Dermatol Venereol Leprol. 2003; 69:135–7. PMid:17642858

14. Radakovic-Fijan S, Furnsinn W, Friedl AM, Honigsmann H, et Al. Oral dexamethasone pulse treatment of vitiligo. J Am Acad Dermatol. 2001; 44:814–7. https://doi.org/10.1067/mjd.2001.113475 PMid:11324340

15. Pastricha JS, Khaitan BK. Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreadind disease. Int J Dermatol. 1993; 32:753–7. https://doi.org/10.1111/j.1365-4632.1993.tb02754.x

16. Gianfaldoni S, Zarrab Z and Lotti T. Phototherapy and Vitiligo Re-pigmentation: From PUVa to Micro-focused Phototherapy. Journal of Pigmentary Disorders. 2014; 1:102.

17. Singh S, Khandpur S, Sharma VK, et al. comparison of efficacy and side effect profile of oral PUVA vs. oral PUVA sol in the treatment of vitilgo: a 36 week prospective study. J Eur Acad Dermatol Venereol. 2013; 27(11):1344-51. https://doi.org/10.1111/jdv.12002 PMid:23066663

18. Kappes UP, Barta U, Merkel U et al. High plasma levels of 8-methoxypsoralen following bath water delivery in dermatological patients. Skin Pharmacol Appl Skin Physiol. 2003; 16(5):305-12. https://doi.org/10.1159/000072070 PMid:12907835

19. Mai DW, Omohundro C, Dijkstra JW, Bailin PL. Childhood vitiligo successfully treated with bath PUVA. Pediatr Dermatol. 1998; 15(1):53-S. https://doi.org/10.1046/j.1525-1470.1998.1998015053.x PMid:9496807

20. Scherschun L, Kim JJ, Lim HW. Narrow-band ultraviolet B is a useful and well-tolerate treatment for vitiligo. J Am Acad Dermatol. 2001; 44(6):999-1003. https://doi.org/10.1067/mjd.2001.114752 PMid:11369913

21. Travis LB, Silverberg NB. Calcipotriene and corticosteroid combination therapy for vitiligo. Pediatr Dermatol. 2004; 21:495-8. https://doi.org/10.1111/j.0736-8046.2004.21418.x PMid:15283800

22. Majid I, Massoud Q, Hassan I, et al. Childhood vitiligo: Response to methylprednisolone oral minipulse therapy and topical fluticasone combination. Indian J Dermatol. 2009; 54:124-7. https://doi.org/10.1016/j.ij jd.2009.04.009PMid:20101306 PMcid:PMC2807150

23. Rath N, Kar HK, Sabhnanai S. An open labeled, comparative clinical study on efficacy and tolerability of oral minipulse of steroid (OMP) alone, OMP with PUVA and broad/narrow band UVB phototherapy in progressive vitiligo. Indian J Dermatol Venereol Leprol. 2008; 74:357-60. https://doi.org/10.4103/0378-6323.42905 PMid:18797057

24. Schallreuter KU, Krüger C, Würfel BA, et al. From basic research to the bedside: Efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo. Int J Dermatol. 2008; 47:743–53. https://doi.org/10.1111/j.1365-4632.2008.03660.x PMid:18613887

25. Tedeschi A, Dall'Oglio F, Micai G, et al. Corrective camouflage in pediatric dermatology. Cutis. 2007; 79:110–2. PMid:17388210

26. Paller AS, Mancini AJ. Disorders of pigmentation. In: Paller AS, Mancini AJ, editors. Hurwitz clinical pediatric dermatology. 3 rd ed. Philadelphia: Elsevier Saunders, 2006: 265-305.

27. Schwartz R, Sepulveda JE, Quintana T. Possible role of psychological and environmental factors in the genetics of childhood vitiligo. Rev Med Chil. 2009; 137:53–62. PMid:19399322

28. Gupta S, Kumar B. Epidermal grafting for vitiligo in adolescents. Pediatr Dermatol. 2002;19:159– 62. https://doi.org/10.1046/j.1525-1470.2002.00035.x PMid:11994184

29. Ashique KT, Kaliyadan F. Long Term Follow-up and Donor Site Changes Evaluation in Suction Blister Epidermal Grafting Done for Stable Vitiligo: A Retrospective Study. Indian J Dermatol. 2015; 60(4):369–72. https://doi.org/10.4103/0378-5154.160482 PMid:26288405 PMcid:PMC4533355

30. Farajzadeh S, Daraei Z, Esfandiarpour I, Hosseini SH. The efficacy of pimecrolimus 1% cream combined with microdermabrasion in the treatment of non-segmental childhood vitiligo: A randomized placebo-controlled study. Pediatr Dermatol. 2009; 26:286-91. https://doi.org/10.1111/j.1525-1470.2009.00926.x PMid:19706089